Mirabegron

For the treatment of overactive bladder (OAB) in adults, the standard starting dose of Mirabegron is 25 mg taken once daily. This dose is effective for many patients and allows the body to adjust to the medication. If the 25 mg dose is well-tolerated but symptoms persist after 4 to 8 weeks, your healthcare provider may increase the dose to 50 mg once daily, which is the maximum recommended dose for adults.

When used in combination with solifenacin (an anticholinergic), the typical starting dose is also 25 mg of Mirabegron daily. Clinical trials have shown that the combination therapy can provide superior symptom relief for some patients compared to using either drug alone. However, your doctor will monitor you closely for increased side effects when using two medications for bladder control.

Mirabegron is approved for pediatric patients aged 3 years and older for the treatment of neurogenic detrusor overactivity (NDO). The dosage in children is strictly based on body weight to ensure safety and efficacy.

• Children weighing 35 kg or more: The starting dose is typically 25 mg once daily. After 4 to 8 weeks, the doctor may increase this to 50 mg once daily if needed.
• Children weighing less than 35 kg: These patients usually require the oral suspension (granules) rather than tablets. Dosing is calculated by the healthcare provider based on the child's exact weight in kilograms. It is critical to use a calibrated measuring device (like an oral syringe) to ensure the child receives the exact prescribed volume.

Mirabegron has not been established as safe or effective for children under the age of 3 years.

Renal Impairment

The kidneys are responsible for clearing about half of the Mirabegron dose from the body. If kidney function is reduced, the drug can build up to toxic levels.

• Mild to Moderate Renal Impairment (eGFR 30 to 89 mL/min): No dose adjustment is typically required, but the 50 mg dose should be used with caution.
• Severe Renal Impairment (eGFR 15 to 29 mL/min): The maximum dose is strictly limited to 25 mg once daily.
• End-Stage Renal Disease (ESRD): Mirabegron is not recommended for patients with eGFR <15 or those requiring hemodialysis.

Hepatic Impairment

The liver metabolizes Mirabegron through various enzyme pathways.

• Mild Hepatic Impairment (Child-Pugh Class A): No dose adjustment is needed.
• Moderate Hepatic Impairment (Child-Pugh Class B): The maximum dose is limited to 25 mg once daily.
• Severe Hepatic Impairment (Child-Pugh Class C): Mirabegron is not recommended for use in this population.

Elderly Patients

No specific dose adjustments are required based solely on age. However, because older adults are more likely to have decreased renal or hepatic function, healthcare providers often start at the lowest effective dose and monitor blood pressure closely.

To get the most benefit from Mirabegron, follow these specific administration guidelines:

1. 1Consistency: You may take Mirabegron with or without food, but you should choose one way and do it the same time every day. This helps maintain steady levels of the drug in your system.
2. 2Swallow Whole: The tablets are extended-release. You must swallow them whole with water. Do not crush, chew, or break the tablets, as this will release all the medication at once, increasing the risk of severe side effects like a dangerous spike in blood pressure.
3. 3Oral Suspension: If using the granules, shake the bottle well for at least 1 minute before measuring the dose. Use only the dosing device provided by the pharmacy. The suspension should be taken within 1 hour of a meal.
4. 4Storage: Store the medication at room temperature (68°F to 77°F) in a dry place. Keep the bottle tightly closed and out of reach of children.

If you miss a dose of Mirabegron, take it as soon as you remember. If it has been more than 12 hours since your scheduled dose, skip the missed dose and take your next dose at the regular time. Do not take two doses at once to make up for a missed one, as this increases the risk of cardiovascular complications.

Signs of a Mirabegron overdose may include an abnormally fast heartbeat (tachycardia), palpitations, and a significant increase in blood pressure. In clinical trials, doses up to 300 mg (six times the max dose) resulted in increased pulse rates and elevated systolic blood pressure. If an overdose is suspected, contact your local poison control center or seek emergency medical attention immediately. Treatment is generally supportive, focusing on monitoring heart rate and blood pressure.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as your symptoms may return quickly.

Mirabegron is generally well-tolerated, but like all medications, it can cause side effects. The most frequently reported side effect in clinical trials is increased blood pressure (hypertension). This occurs because, while Mirabegron is selective for beta-3 receptors in the bladder, at therapeutic doses, it may have minor effects on beta-receptors in the heart and blood vessels. Patients may not 'feel' high blood pressure, which is why regular monitoring is essential. Other very common effects include:

• Nasopharyngitis: Symptoms similar to the common cold, such as a runny nose, sneezing, or sore throat.
• Urinary Tract Infection (UTI): Because the medication changes how the bladder relaxes and stores urine, some patients may be more prone to bacterial growth. Symptoms include burning during urination, cloudy urine, or pelvic pain.
• Headache: This is usually mild to moderate and often diminishes as the body adjusts to the medication over the first few weeks.

These side effects occur in a smaller percentage of the population but are still documented in clinical literature:

• Gastrointestinal Issues: Constipation, diarrhea, and nausea. While less common than with anticholinergic drugs, these can still occur.
• Dizziness: Some patients may feel lightheaded, particularly when standing up quickly. This is often related to changes in blood pressure.
• Tachycardia (Fast Heart Rate): You may feel like your heart is racing or 'fluttering' in your chest. If this becomes persistent or uncomfortable, notify your doctor.
• Dry Mouth: Although Mirabegron is designed to avoid this, a small number of patients still report a dry sensation in the mouth or throat.
• Back Pain or Joint Pain: Non-specific musculoskeletal discomfort has been reported by some users.

Rare but documented side effects include:

• Atrial Fibrillation: An irregular, often rapid heart rate that can increase the risk of strokes or heart failure.
• Blurred Vision: Changes in the ability to focus or a sensation of 'dry eyes.'
• Skin Rash or Urticaria (Hives): This may indicate a mild allergic sensitivity to the drug.
• Vulvovaginal Pruritus: Itching in the vaginal area, sometimes associated with changes in the local environment or secondary infections.

> Warning: Stop taking Mirabegron and call your doctor immediately or seek emergency care if you experience any of the following:

1. 1Severe Hypertension: A sudden, massive increase in blood pressure (e.g., 180/110 mmHg or higher). Symptoms can include severe headache, confusion, chest pain, or vision changes.
2. 2Angioedema: This is a life-threatening allergic reaction characterized by swelling of the face, lips, tongue, or throat. It can happen at any time during treatment—even months after starting. If you have difficulty breathing or swallowing, call 911 immediately.
3. 3Urinary Retention: This occurs when you are unable to empty your bladder at all. This is a medical emergency and is more common in men with bladder outlet obstruction (like an enlarged prostate) or those taking anticholinergic medications simultaneously.
4. 4Severe Cardiac Arrhythmias: If you feel your heart skipping beats or beating extremely fast accompanied by shortness of breath or fainting.

The long-term safety of Mirabegron has been studied for up to one year in clinical trials. The primary concern with prolonged use is the cumulative effect on cardiovascular health. Because Mirabegron can cause sustained increases in blood pressure, long-term users must have their blood pressure checked at every doctor's visit. There is currently no evidence that Mirabegron causes cognitive decline (dementia), which is a significant advantage over long-term use of older anticholinergic OAB medications.

No FDA black box warnings for Mirabegron. Unlike some other urological or cardiovascular medications, the FDA has not required a boxed warning for Mirabegron. However, the warnings regarding high blood pressure and angioedema are considered 'Major Warnings' within the prescribing information and should be treated with the highest level of caution.

Report any unusual symptoms, especially those affecting your heart rate or ability to urinate, to your healthcare provider promptly. Keeping a 'bladder diary' can help you and your doctor track both the effectiveness of the drug and any potential side effects.

Mirabegron is a powerful medication that interacts with the autonomic nervous system. Before starting this drug, it is vital to understand that it is not suitable for everyone. The most critical safety point is the risk of elevated blood pressure. Mirabegron can increase blood pressure significantly, even in patients who previously had normal readings. If you have a history of hypertension, your condition must be well-controlled before you begin Mirabegron. Your healthcare provider should measure your blood pressure at the start of therapy and periodically thereafter.

Another key safety consideration is the risk of urinary retention. Because Mirabegron relaxes the bladder muscle, it may make it harder for the bladder to contract when it is actually time to urinate. This is particularly risky for patients with a physical blockage in the urinary tract, such as an enlarged prostate (Benign Prostatic Hyperplasia) or those taking other medications that also relax the bladder. If you find that you are straining to urinate or cannot empty your bladder, seek medical help immediately.

No FDA black box warnings for Mirabegron. While the drug carries significant warnings for hypertension and angioedema, it has not met the FDA criteria for a boxed warning as of 2026.

• Allergic Reactions / Angioedema: There have been reports of angioedema (swelling under the skin) involving the face, lips, tongue, and larynx. In some cases, this occurred after the first dose, while in others, it occurred after multiple doses. If swelling occurs, the drug must be discontinued immediately and never restarted.
• Cardiovascular Risks: Beyond hypertension, Mirabegron can increase heart rate (tachycardia). Patients with pre-existing heart conditions, such as arrhythmias or ischemic heart disease, should use this medication with extreme caution.
• Bladder Outlet Obstruction (BOO): Men with an enlarged prostate are at a higher risk of developing acute urinary retention while taking Mirabegron. The drug should be administered with caution in this population.
• QT Prolongation: While Mirabegron at standard doses (25mg/50mg) does not significantly prolong the QT interval (a measure of heart rhythm), supratherapeutic doses (over 100mg) have shown the potential to do so. Avoid taking more than the prescribed dose.

To ensure your safety while taking Mirabegron, your healthcare provider will likely implement the following monitoring schedule:

1. 1Blood Pressure: Baseline measurement followed by checks at 2 weeks, 4 weeks, and then every 3-6 months.
2. 2Heart Rate: Monitoring for palpitations or unexplained increases in pulse.
3. 3Renal and Hepatic Function: Annual blood tests (BUN, Creatinine, Liver Enzymes) to ensure the organs responsible for clearing the drug are functioning adequately. If kidney or liver function declines, your dose may need to be lowered.
4. 4Post-Void Residual (PVR): In patients at risk for retention, a doctor may use an ultrasound to check how much urine remains in the bladder after you try to empty it.

Mirabegron generally does not cause drowsiness or significant cognitive impairment. However, because it can cause dizziness or blurred vision in some individuals, you should observe how the medication affects you before driving a car or operating heavy machinery. If you feel lightheaded, avoid these activities and consult your doctor.

There is no direct chemical interaction between Mirabegron and alcohol. However, alcohol is a known bladder irritant and a diuretic (it increases urine production). Consuming alcohol while treating OAB may counteract the benefits of Mirabegron and worsen symptoms of urgency and frequency. Additionally, both alcohol and Mirabegron can affect blood pressure; combining them may lead to unpredictable changes in your readings.

Mirabegron does not require a tapering schedule. You can generally stop taking it without experiencing a withdrawal syndrome. However, because the drug treats a chronic condition, your overactive bladder symptoms (urgency, frequency, leakage) will likely return within a few days of stopping the medication. Always discuss your decision to stop the medication with your doctor to explore alternative treatments.

> Important: Discuss all your medical conditions, especially heart disease, high blood pressure, and kidney or liver problems, with your healthcare provider before starting Mirabegron.

While there are few absolute contraindications for Mirabegron, it should never be used in patients with severe, uncontrolled hypertension (defined as systolic BP ≥180 mmHg and/or diastolic BP ≥110 mmHg). Using Mirabegron in this state can trigger a hypertensive crisis, potentially leading to stroke or organ damage.

Additionally, Mirabegron should not be used in combination with other potent Beta-3 agonists or medications that significantly increase heart rate if the patient has an underlying cardiac condition, as the additive effects on the heart can be dangerous.

Mirabegron is a moderate inhibitor of the CYP2D6 enzyme. This is a critical interaction because many common medications are broken down by this enzyme. When Mirabegron inhibits CYP2D6, the levels of these other drugs can rise to toxic levels in the blood. Examples include:

• Metoprolol and Propranolol: Used for heart rate and blood pressure. Mirabegron can increase the concentration of these drugs, leading to an abnormally slow heart rate (bradycardia).
• Flecainide and Propafenone: Anti-arrhythmic drugs with a 'narrow therapeutic index' (the difference between a safe dose and a toxic dose is small). Combining these with Mirabegron requires intense cardiac monitoring.
• Thioridazine: An antipsychotic. Increased levels can cause dangerous heart rhythm disturbances.
• Tamoxifen: A breast cancer medication. Tamoxifen requires CYP2D6 to be converted into its active form (endoxifen). Mirabegron may reduce the effectiveness of Tamoxifen, potentially impacting cancer treatment outcomes.

• Digoxin: Mirabegron is a weak inhibitor of P-glycoprotein (P-gp), a transporter that helps move drugs out of cells. Taking Mirabegron with Digoxin can increase Digoxin levels by about 27%. Patients on Digoxin should have their blood levels monitored and their dose adjusted by a doctor when starting or stopping Mirabegron.
• Warfarin: While Mirabegron does not significantly change the INR (clotting time), patients on blood thinners should always be monitored more closely when starting any new medication.
• Anticholinergic Drugs: Taking Mirabegron with drugs like oxybutynin, tolterodine, or benztropine can increase the risk of urinary retention and severe constipation. While the combination of Mirabegron and Solifenacin is FDA-approved, it must be managed carefully.

• High-Fat Meals: As noted in the pharmacokinetics section, a high-fat meal can reduce the peak concentration of Mirabegron tablets. While the drug can be taken with or without food, you should be consistent.
• Grapefruit Juice: Unlike many other drugs, Mirabegron is not significantly affected by grapefruit juice, as it is not solely dependent on the CYP3A4 pathway for metabolism.
• Caffeine: Caffeine is a known bladder stimulant and diuretic. High intake of coffee, tea, or energy drinks can worsen OAB symptoms and may also increase the heart rate effects of Mirabegron.

• St. John’s Wort: This herbal supplement induces (speeds up) CYP3A4 enzymes. It may lower the concentration of Mirabegron in the blood, making it less effective.
• Garlic and Ginkgo: These can have mild blood-thinning effects. While not a direct interaction, patients should be cautious if they are also taking other medications that affect circulation.
• Ephedra/Ma Huang: These contain stimulants that can dangerously increase blood pressure and heart rate when combined with a beta-3 agonist like Mirabegron.

Mirabegron is not known to interfere with common laboratory tests, such as urinalysis, blood glucose, or cholesterol panels. However, it is always important to inform the laboratory and your doctor of all medications you are taking before any diagnostic testing.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is the only way to prevent dangerous drug-drug interactions.

There are specific scenarios where Mirabegron must NEVER be used because the risks far outweigh any potential benefits:

1. 1Hypersensitivity: If you have had a previous allergic reaction to Mirabegron or any of the inactive ingredients in the tablet (such as polyethylene oxide or magnesium stearate), you must not take this drug. Reactions can range from mild rashes to life-threatening angioedema.
2. 2Severe Uncontrolled Hypertension: Patients with a blood pressure of 180/110 mmHg or higher are strictly prohibited from using Mirabegron. The drug’s mechanism involves stimulating beta-adrenergic receptors, which can further elevate blood pressure, potentially triggering a hypertensive emergency, stroke, or myocardial infarction (heart attack).
3. 3Severe Hepatic Impairment (Child-Pugh Class C): Because the liver is a primary site for Mirabegron metabolism, patients with severe liver failure cannot process the drug. This leads to dangerously high systemic levels of the medication.
4. 4End-Stage Renal Disease (ESRD): Patients with a GFR <15 mL/min or those on dialysis should not use Mirabegron, as the kidneys cannot excrete the drug, leading to toxicity.

These are conditions where the drug may be used, but only with extreme caution and frequent medical oversight:

• Bladder Outlet Obstruction (BOO): Men with significantly enlarged prostates or patients with urethral strictures. The relaxation of the detrusor muscle can 'tip the balance' and lead to a total inability to urinate (acute urinary retention).
• Controlled Hypertension: If your blood pressure is high but managed with medication, you can take Mirabegron, but you must monitor your readings daily at home for the first few weeks.
• History of QT Prolongation: If you have a known heart rhythm disorder or take other medications that affect the QT interval, your doctor will need to perform baseline and follow-up EKGs.
• Moderate Renal or Hepatic Impairment: These patients require a mandatory dose cap of 25 mg daily.

There is no known cross-sensitivity between Mirabegron and antimuscarinic OAB drugs (like oxybutynin). However, patients who have experienced angioedema with other drugs—especially ACE inhibitors used for blood pressure—should be monitored very closely, as they may be more predisposed to swelling of the airway.

> Important: Your healthcare provider will evaluate your complete medical history, including your current blood pressure and organ function, before prescribing Mirabegron to ensure it is safe for you.

Mirabegron is currently classified as a medication where the risks during pregnancy are not fully known. In animal studies (rats and rabbits), very high doses of Mirabegron were associated with lower fetal body weights and increased fetal mortality. There are no adequate and well-controlled studies in pregnant women.

• First Trimester: Caution is advised as this is the period of organogenesis (organ formation).
• Third Trimester: There is a theoretical risk that beta-3 agonists could interfere with uterine contractions, though this has not been clinically proven for Mirabegron.

Healthcare providers typically only prescribe Mirabegron during pregnancy if the potential benefit to the mother justifies the potential risk to the fetus. If you become pregnant while taking this drug, notify your doctor immediately.

It is not known whether Mirabegron is excreted in human breast milk. However, animal studies have shown that the drug is present in the milk of lactating rats. Because many drugs are excreted in human milk and the potential for serious adverse reactions in a nursing infant (such as increased heart rate or blood pressure) exists, a decision must be made whether to discontinue nursing or discontinue the drug. Most clinicians recommend avoiding Mirabegron while breastfeeding if possible.

Mirabegron is FDA-approved for the treatment of Neurogenic Detrusor Overactivity (NDO) in children aged 3 years and older. It is not approved for 'standard' overactive bladder in children; its use is limited to those with neurological conditions.

• Dosing: Must be weight-based.
• Safety: The side effect profile in children is similar to adults, with increased blood pressure and nasopharyngitis being the most common. Long-term effects on growth and development are still being monitored in post-marketing studies.

Clinical trials included a significant number of patients aged 65 and over. Data suggests that there are no overall differences in safety or effectiveness between older and younger patients. However, the elderly are more likely to have:

• Reduced Renal Clearance: Requiring lower doses.
• Polypharmacy: Increased risk of drug interactions with heart medications.
• Cardiovascular Sensitivity: Older hearts may be more sensitive to the tachycardia (fast heart rate) caused by the drug.

Mirabegron is often preferred in the elderly over anticholinergics because it does not cross the blood-brain barrier significantly and therefore does not cause the confusion or memory loss associated with drugs like oxybutynin.

For patients with a GFR between 15 and 29 mL/min, the dose must not exceed 25 mg. Mirabegron is not removed by hemodialysis; therefore, patients on dialysis should not use this medication. Regular monitoring of serum creatinine is recommended for all patients with known kidney disease.

For patients with moderate hepatic impairment (Child-Pugh Class B), the dose is capped at 25 mg. The drug has not been studied in patients with severe hepatic impairment (Class C), and its use is contraindicated in that group due to the risk of extreme drug accumulation.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have any degree of kidney or liver disease.

Mirabegron is a selective beta-3 adrenergic receptor agonist. To understand its action, one must look at the autonomic control of the bladder. During the storage phase, the sympathetic nervous system releases norepinephrine, which binds to beta-3 receptors on the detrusor muscle. This binding activates the Gs-protein/adenylyl cyclase pathway, increasing intracellular cyclic AMP (cAMP). High cAMP levels lead to a reduction in intracellular calcium and the activation of potassium channels, resulting in smooth muscle relaxation.

By pharmacologically stimulating these receptors, Mirabegron enhances this natural relaxation process. This increases the 'voiding threshold'—the amount of urine the bladder can hold before the urge to urinate becomes uncontrollable. Unlike anticholinergics, Mirabegron does not inhibit the voiding contraction (which is mediated by muscarinic M3 receptors), meaning it is less likely to cause a total inability to urinate in healthy individuals.

The primary pharmacodynamic effect of Mirabegron is an increase in bladder capacity and a decrease in the frequency of involuntary detrusor contractions. In clinical urodynamic studies, Mirabegron has been shown to increase the volume at first contraction and increase the total bladder capacity. The onset of action is not immediate; while some patients notice improvement within 1-2 weeks, the full therapeutic effect usually takes 4 to 8 weeks of consistent daily use. There is no evidence of 'tachyphylaxis' (tolerance), meaning the drug remains effective over long periods of use.

| Parameter | Value |

|---|---|

| Bioavailability | 29% (25 mg) to 35% (50 mg) |

| Protein Binding | ~71% (Albumin and Alpha-1 acid glycoprotein) |

| Half-life | Approximately 50 hours |

| Tmax | 3.5 to 5 hours |

| Metabolism | CYP3A4, CYP2D6, Glucuronidation, Amide Hydrolysis |

| Excretion | Renal 55% (25% unchanged), Fecal 34% |

• Molecular Formula: C21H24N4O2S
• Molecular Weight: 396.51 g/mol
• Solubility: Mirabegron is a white powder that is practically insoluble in water but soluble in methanol and dimethyl sulfoxide (DMSO).
• Structure: It contains a 2-amino-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-thiazoleacetamide structure, which allows it to fit specifically into the binding pocket of the beta-3 adrenergic receptor.

Mirabegron belongs to the therapeutic class of Beta-3 Adrenergic Agonists. It is currently the primary medication in this class for urological use. Other medications for OAB, such as oxybutynin, tolterodine, and solifenacin, belong to the Antimuscarinic (Anticholinergic) class. Vibegron (Gemtesa) is another newer member of the beta-3 agonist class that works similarly to Mirabegron.